{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:27:33Z","timestamp":1770884853728,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5U01DA046910"],"award-info":[{"award-number":["5U01DA046910"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>During the COVID-19 pandemic, federal regulations in the USA for methadone treatment of opioid use disorder (OUD) were temporarily revised to reduce clinic crowding and promote access to treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>As part of a study seeking to implement interim methadone without routine counseling to hasten treatment access in Opioid Treatment Programs with admission delays, semi-structured qualitative interviews were conducted via Zoom with participating staff (N\u2009=\u200911) in six OTPs and their State Opioid Treatment Authorities (SOTAs; N\u2009=\u20095) responsible for overseeing the OTPs\u2019 federal regulatory compliance. Participants discussed their views on the response of OTPs in their states to the pandemic and the impact of the COVID-related regulatory flexibilities on staff, established patients, and new program applicants. Interviews were audio recorded, transcribed, and a content analysis was conducted using ATLAS.ti.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All SOTAs requested the blanket take-home exemption and supported the use of telehealth for counseling. Participants noted that these changes were more beneficial for established patients than program applicants. Established patients were able to obtain a greater number of take-homes and attend individual counseling remotely. Patients with limited resources had greater difficulty or were unable to access remote counseling<jats:italic>.<\/jats:italic> The convenience of intake through telehealth did not extend to new program applicants because the admission physical exam requirement was not waived.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The experienced reflections of SOTAs and OTP providers on methadone practice changes during the COVID-19 pandemic offer insights on SAMHSA\u2019s proposed revisions to its OTP regulations.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Clinicaltrials.gov # NCT04188977.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00417-7","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:02:49Z","timestamp":1697536969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct04188977","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-1085","authenticated-orcid":false,"given":"Shannon Gwin","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Jester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Gryczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Whitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Halsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104058","author":"A Adams","year":"2023","unstructured":"Adams A, Blawatt S, MacDonald S, Finnick R, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E. Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: a qualitative systematic review. Int J Drug Policy. 2023. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104058.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"417_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jsat.2011.01.009","volume":"41","author":"AA Al-Tayyib","year":"2011","unstructured":"Al-Tayyib AA, Koester S. Injection drug users\u2019 experience with and attitudes toward methadone clinics in Denver. CO J Subst Abuse Treat. 2011;41(1):30\u20136.","journal-title":"CO J Subst Abuse Treat"},{"issue":"6","key":"417_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","volume":"47","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722\u20139. https:\/\/doi.org\/10.1080\/00952990.2021.1979991.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"417_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/00952990.2021.1903023","volume":"47","author":"B Andraka-Christou","year":"2021","unstructured":"Andraka-Christou B, Bouskill K, Haffajee RL, Randall-Kosich O, Golan M, Totaram R, Gordon AJ, Stein BD. Common themes in early state policy responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021;47(4):486\u201396. https:\/\/doi.org\/10.1080\/00952990.2021.1903023.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"417_CR5","unstructured":"ATLASti.com. (2022). ATLAS.ti Scientific Software Development GmbH [ATLAS.ti 22 Windows]."},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449. https:\/\/doi.org\/10.1016\/j.jsat.2021.108449.","journal-title":"J Subst Abuse Treat"},{"key":"417_CR7","unstructured":"Medication Assisted Treatment For Opioid Use Disorders, 42 C.F.R. \u00a7 8, (2001). https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-8?toc=1"},{"issue":"1","key":"417_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","volume":"106","author":"L Degenhardt","year":"2011","unstructured":"Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32\u201351. https:\/\/doi.org\/10.1111\/j.1360-0443.2010.03140.x.","journal-title":"Addiction"},{"key":"417_CR9","unstructured":"Federal Register. (2022). Medications for the Treatment of Opioid Use Disorder: A Proposed Rule by the Health and Human Services Department on 12\/16\/2022. Retrieved 05\/26\/2023 from https:\/\/www.federalregister.gov\/documents\/2022\/12\/16\/2022-27193\/medications-for-the-treatment-of-opioid-use-disorder"},{"key":"417_CR10","doi-asserted-by":"publisher","first-page":"108276","DOI":"10.1016\/j.jsat.2021.108276","volume":"123","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276. https:\/\/doi.org\/10.1016\/j.jsat.2021.108276.","journal-title":"J Subst Abuse Treat"},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"109049","DOI":"10.1016\/j.drugalcdep.2021.109049","volume":"228","author":"LA Goldsamt","year":"2021","unstructured":"Goldsamt LA, Rosenblum A, Appel P, Paris P, Nazia N. The impact of COVID-19 on opioid treatment programs in the United States. Drug Alcohol Depend. 2021;228:109049. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109049.","journal-title":"Drug Alcohol Depend"},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"108223","DOI":"10.1016\/j.jsat.2020.108223","volume":"124","author":"MA Hatch-Maillette","year":"2021","unstructured":"Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: provider perspectives. J Subst Abuse Treat. 2021;124:108223. https:\/\/doi.org\/10.1016\/j.jsat.2020.108223.","journal-title":"J Subst Abuse Treat"},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.jsat.2022.108801","volume":"141","author":"KA Hoffman","year":"2022","unstructured":"Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIlveen JW, Korthuis PT, McCarty D. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis. J Subst Abuse Treat. 2022;141:108801.","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"417_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"key":"417_CR15","volume-title":"Federal regulation of methadone treatment","author":"Institute of Medicine","year":"1995","unstructured":"Institute of Medicine. Federal regulation of methadone treatment. Washington: National Academies Press; 1995."},{"key":"417_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.1776","author":"CM Jones","year":"2022","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiat. 2022. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1776.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"417_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsat.2013.08.009","volume":"46","author":"VL King","year":"2014","unstructured":"King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS. A randomized trial of web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat. 2014;46(1):36\u201342. https:\/\/doi.org\/10.1016\/j.jsat.2013.08.009.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"417_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/ADM.0000000000000981","volume":"16","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Bandara S. Shifting medication treatment practices in the COVID-19 pandemic: a statewide survey of Pennsylvania opioid treatment programs. J Addict Med. 2022;16(6):645.","journal-title":"J Addict Med"},{"issue":"9","key":"417_CR19","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/add.14991","volume":"115","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Mojtabai R, Stuart EA, Fingerhood M, Agus D, Lyons BC, Weiner JP, Saloner B. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683\u201394. https:\/\/doi.org\/10.1111\/add.14991.","journal-title":"Addiction"},{"issue":"3","key":"417_CR20","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","volume":"8","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Levin E, Dooling BC. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. Lancet Public Health. 2023;8(3):e238\u201346.","journal-title":"Lancet Public Health"},{"key":"417_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1986768","author":"XA Levander","year":"2021","unstructured":"Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: a multistate survey of opioid treatment program leadership. Subst Abus. 2021. https:\/\/doi.org\/10.1080\/08897077.2021.1986768.","journal-title":"Subst Abus"},{"key":"417_CR22","doi-asserted-by":"publisher","unstructured":"Lin C, Pham H, Zhu Y, Clingan SE, Lin LA, Murphy SM, Campbell CI, Sorrell TR, Liu Y, Mooney LJ. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2022. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109711.","DOI":"10.1016\/j.drugalcdep.2022.109711"},{"issue":"5","key":"417_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1176\/appi.ps.202100088","volume":"73","author":"TL Mark","year":"2022","unstructured":"Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction treatment and telehealth: review of efficacy and provider insights during the COVID-19 pandemic. Psychiatr Serv. 2022;73(5):484\u201391.","journal-title":"Psychiatr Serv"},{"issue":"8","key":"417_CR24","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/add.15886","volume":"117","author":"JW McIlveen","year":"2022","unstructured":"McIlveen JW, Hoffman KA, McCarty D. State policy uptake does not require formal action: a comment on Nesoff <i>et al<\/i>. Addiction. 2022;117(8):2359\u201360. https:\/\/doi.org\/10.1111\/add.15886.","journal-title":"Addiction"},{"key":"417_CR25","unstructured":"National Association of State Alcohol and Drug Abuse Disorders. (2023). Opioid Treatment Network. https:\/\/nasadad.org\/state-opioid-treatment-authorities\/"},{"key":"417_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2217-0","author":"MJ Ritchie","year":"2017","unstructured":"Ritchie MJ, Parker LE, Edlund CN, Kirchner JE. Using implementation facilitation to foster clinical practice quality and adherence to evidence in challenged settings: a qualitative study. BMC Health Serv Res. 2017. https:\/\/doi.org\/10.1186\/s12913-017-2217-0.","journal-title":"BMC Health Serv Res"},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"103537","DOI":"10.1016\/j.drugpo.2021.103537","volume":"101","author":"B Saloner","year":"2022","unstructured":"Saloner B, Krawczyk N, Solomon K, Allen ST, Morris M, Haney K, Sherman SG. Experiences with substance use disorder treatment during the COVID-19 pandemic: findings from a multistate survey. Int J Drug Policy. 2022;101:103537.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"417_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","volume":"63","author":"RP Schwartz","year":"2006","unstructured":"Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O\u2019Grady KE, Battjes RJ. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102\u20139. https:\/\/doi.org\/10.1001\/archpsyc.63.1.102.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"417_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jsat.2011.01.008","volume":"41","author":"RP Schwartz","year":"2011","unstructured":"Schwartz RP, Kelly SM, O\u2019Grady KE, Gandhi D, Jaffe JH. Interim methadone treatment compared to standard methadone treatment: 4-month findings. J Subst Abuse Treat. 2011;41(1):21\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2011.01.008.","journal-title":"J Subst Abuse Treat"},{"key":"417_CR30","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"key":"417_CR31","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). Methadone Take-Home Flexibilities Extension Guidance. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines\/methadone-guidance"},{"key":"417_CR32","unstructured":"Substance Abuse and Mental Health Services Adminstration (SAMHSA). (2020). Opioid Treatment Program (OTP) Guidance. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf"},{"issue":"1","key":"417_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/08897077.2022.2060438","volume":"43","author":"LW Suen","year":"2022","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. \u201cThe idea is to help people achieve greater success and liberty\u201d: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abuse. 2022;43(1):1147\u201354.","journal-title":"Subst Abuse"},{"key":"417_CR34","unstructured":"The Pew Charitable Trusts. (2022). Overview of opioid treatment program regulations by state: Restrictive rules put evidence-based medication treatment out of reach for many. Retrieved March 28, 2023, https:\/\/www.pewtrusts.org\/-\/media\/assets\/2022\/09\/overview-of-opioid-treatment-program-regulations-by-state.pdf"},{"key":"417_CR35","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.1016\/j.jsat.2021.108514","volume":"132","author":"PC Treitler","year":"2022","unstructured":"Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Subst Abuse Treat. 2022;132:108514. https:\/\/doi.org\/10.1016\/j.jsat.2021.108514.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"417_CR36","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622\u2013e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"417_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/ADM.0b013e3182584772","volume":"6","author":"AY Walley","year":"2012","unstructured":"Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH, Alford DP. Methadone dose, take home status, and hospital admission among methadone maintenance patients. J Addict Med. 2012;6(3):186\u201390. https:\/\/doi.org\/10.1097\/ADM.0b013e3182584772.","journal-title":"J Addict Med"},{"key":"417_CR38","doi-asserted-by":"publisher","first-page":"103591","DOI":"10.1016\/j.drugpo.2022.103591","volume":"102","author":"C Welsh","year":"2022","unstructured":"Welsh C, Doyon S, Hart K. Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Int J Drug Policy. 2022;102:103591. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103591.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"417_CR39","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2105\/ajph.81.9.1185","volume":"81","author":"SR Yancovitz","year":"1991","unstructured":"Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, Robinson JW. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185\u201391. https:\/\/doi.org\/10.2105\/ajph.81.9.1185.","journal-title":"Am J Public Health"},{"issue":"2","key":"417_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/ijerph6020787","volume":"6","author":"ND Zaller","year":"2009","unstructured":"Zaller ND, Bazazi AR, Velazquez L, Rich JD. Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health. 2009;6(2):787\u201397.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00417-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:24:44Z","timestamp":1700421884000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00417-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00417-7","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human Subjects oversight was provided by the Western Institutional Review Board (WIRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Unrelated to the present study, Dr. Mitchell is MPI on a NIDA study that was provided medication in-kind by Braeburn. Dr. Schwartz has provided consultation to Verily Life Sciences and Dr. Gryczynski reports part ownership of COG Analytics and a research grant from Indivior. Both have reported serving as PI on a NIDA grant that was provided medication in-kind by Indivior and Alkermes. All other authors report no additional conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}